



PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Comess, et al.

Serial No.: 10/667,358

Filed: September 23, 2003

Title: SULFONAMIDES HAVING  
ANTIANGIOGENIC AND ANTICANCER  
ACTIVITY

Case No.: 6983USP1

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Group Art No.: 1614

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450 on:

Date of Deposit: February 20, 2004

Tanya Parent 2/20/04  
Tanya Parent Date

TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith for the patent application identified above entitled SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY are the following:

1. Information Disclosure Statement;
2. Form PTO 1449, in duplicate;
3. Reference as cited on PTO 1449 (8 reference); and
4. Return Receipt Postcard.

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.

Respectfully submitted,  
Comes, et al.

ABBOTT LABORATORIES  
Customer Number 23492  
Telephone: (847) 937-0042  
Facsimile: (847) 938-2623

Gregory W. Steele  
Gregory W. Steele  
Registration No. 33,796  
Attorney for Applicants



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Comess, et al.

Serial No.: 10/667,358

Filed: September 23, 2003

Title: SULFONAMIDES HAVING  
ANTIANGIOGENIC AND ANTICANCER  
ACTIVITY

Case No.: 6983USP1

Group Art No.: 1614

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450 on:

Date of Deposit: February 20, 2004

Tanya Parent 2/20/04  
Tanya Parent Date

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed, to the knowledge of the undersigned, before the mailing date of a first Office Action on the merits. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.

Respectfully submitted,  
Comes, et al.

ABBOTT LABORATORIES  
Customer Number 23492  
Telephone: (847) 937-0042  
Facsimile: (847) 938-2623

Gregory W. Steele  
Gregory W. Steele  
Registration No. 33,796  
Attorney for Applicants



DATE: February 20, 2004 SHEET 1 of 1

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

6983USP1

SERIAL NO.

10/667,358

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

APPLICANT(S)

Comess, et al.

FILING DATE

September 23, 2003

GROUP

1614

(Use several sheets if necessary)

(37 CFR 1.98 (b))

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
	A1	5,929,097	07/27/99	Levin et al.			
	A2	6,335,334	01/01/02	Schindler et al.			

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Griffith et al., "Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin," Chemistry & Biology 4(5):461-471 (1997)
C2	Hodgson et al., "Reactions of Aromatic Nitro-compounds with Alkaline Sulphides." J. Chem. Soc. 1187 (1949)
C3	Showalter et al., "Concise syntheses of the novel 1H-pyrrolo[3,2-g]quinazoline ring system and its [2,3-f] angular isomer," J. Org. Chem. 61:1155-1158 (1996)
C4	Sin et al., "The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2," Proc. Natl. Acad. Sci. USA 94:6099-6103 (1997)
C5	Tilley et al., "Synthesis of 5-alkoxyanthranilic acids," Org. Prep. Proc. Int. 13(3-4):189-196 (1981)
C6	Tomioka et al., "Studies on aromatic nitro compounds. V. A simple one-pot preparation of o-aminoaroylnitriles from some aromatic nitro compounds," Chem. Pharm. Bull. 33(4):1360-1366 (1985)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)